Comprehensive Medication Management Services as a Solution to Medication Mismanagement: A European Perspective

Iva Mucalo1, Andrea Brajković2, Ivona Jukic3, Danijela Jonjić1, Dagmar Radin3, Antonija Balenović4, Djenane Ramalho de Oliveira5

1 University of Zagreb Faculty of Pharmacy and Biochemistry, A. Kovačica 1, Zagreb, Croatia
2 Community pharmacy Mundir Pharm, Branimirova ulica 65, Zagreb, Croatia
3 University of Zagreb Faculty of Political Science, Lepusica 6, Zagreb, Croatia
4 Health Centre Zagreb Centar, Runjaninova 4, Zagreb, Croatia
5 Centre for Pharmacaceutical Care Studies (Centro de Estudos Atencao Farmaceutica), Federal University of Minas Gerais, Belo Horizonte, MG, Brazil

ABSTRACT:
Due to an increase in the prevalence of chronic diseases, medication use and their cost is rising rapidly. This scenario render chronic patients at an increased risk of experiencing drug therapy problems, subsequently leading to unfavourable clinical and economic outcomes. Thus, to ensure patients' optimal medication use and improve their clinical outcomes, a comprehensive and systematic management of medications is deemed crucial. Hence, Comprehensive Medication Management (CMM) services offered by trained pharmacists can fill this gap by decreasing the unnecessary and often harmful use of medicines and consequent resulting complications. Collaborative practice between pharmacists and general practitioners, together with patients' active participation in the definition of treatment regimens, plays an important role in the effectiveness of CMM services. CMM services is defined as the standard of care that ensures each patient's medications (prescription, non-prescription, alternative, traditional, vitamins, or nutritional supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given the comorbidities and other medications taken, and that the patient is able to take them as intended. It includes an individualized care plan that achieves the intended goals of therapy with appropriate follow-up to determine actual patient outcomes.

Apart from the USA, several countries (e.g. Australia, Canada and Brazil) have managed to integrate CMM services into their existing health care system at the primary care level. However, in Europe, in spite of the widespread recognition of the need for medication management services, initiation and implementation of CMM services are lagging behind. Hence, for CMM services to become a reality in Europe and elsewhere, numerous prerequisites need to be accomplished, including policies and legal regulations supporting the provision of CMM services on a much larger scale, clearly defined and standardized professional practice and common language shared among the pharmacists, and well trained and experienced practitioners providing full-time, direct patient care.

KEYWORDS: medication management, comprehensive medication management services, chronic diseases, pharmaceutical care

SAŽETAK:
Sveobuhvatna usluga upravljanja farmakoterapijom kao rješenje za propuste u propisivanju lijekova: europska perspektiva

Zbog porasta prevalencije kroničnih bolesti, potrošnja lijekova ubrzano raste. Uslijed toga, toki bolesnici su izloženi povećanom riziku pojava terapijskih problema što dovodi do nepovoljnih kliničkih i ekonomskih ishoda liječenja. Stoga se smatra da je sveobuhvatno i sustavno upravljanje farmakoterapijom ključno za osiguranje optimalne ulaze liječenja i za poboljšanje kliničkih i ekonomskih ishoda liječenja. Sveobuhvatna usluga upravljanja farmakoterapijom (engl. Comprehensive Medication Management Services, CMM services) koju provode posebno educirani ljekarnici može ponuditi rješenje za ovaj problem, smanjujući nepotrebnu, a često i štetnu primjenu lijekova te njene posljedične komplikacije. Kollaborativna praksa ljekarnika i liječnika obiteljske medicine, koja uključuje i aktivno sudjelovanje pacijenata u kreiranju terapijskih režima, važan je čimbenik koji doprinosi učinkovitosti CMM usluge. CMM usluga se smatra da je standard skrbi koji osigurava da se svakom pacijentu pojedinačno procjenjuju svi lijekovi (u receptnom ili bezreceptnom režimu, biljni, tradicionalni), vitamini ili dodaci prehrani koje uzima, kako bi se za svaki od njih utvrdilo je li prikladan za pacijenta, je li učinkovit za pacijentovo zdravstveno stanje, je li siguran s obzirom na komorbiditete i druge lijekove koje pacijent uzima, te je li pacijent sposoban i u mogućnosti uzimati lijekove kako treba. Usluga sadrži individualizirani plan skrbi kojim se postižu predviđeni ciljevi terapije kao i odgovarajuće praćenje (follow-up) kako bi se utvrdili stvarni ishodi liječenja. Pored SAD-a, nekoliko je drugih zemalja (Australija, Kanada i Brazil) uspjelo integrirati CMM usluge u svoje postojeće sustave primarne zdravstvene zaštite. Međutim, u Europi, unatoč raširenosti spoznaje o potrebi za upravljanjem farmakoterapijom, razvoj i implementacija CMM usluge zaostaje. Kako bi se CMM usluge realizirale u Europi i ostalim zemljama, potrebno je ispuniti brojne preduvjete, uključujući donošenje politika i zakonskih propisa koji podržavaju pružanje CMM usluga u mnogo većem obimu, ostvarivanje jasno definirane i standardizirane profesionalne prakse i zajedničkog jezika ljekarnika, te stvaranje dobro educiranih i iskusnih ljekarnika koji u punom radnom vremenu pružaju izazivnu skrb pacijentima.

KLJUČNE RJEŠEĆI: upravljanje farmakoterapijom, sveobuhvatna usluga upravljanja farmakoterapijom, kronične bolesti, ljekarnička skrb
**INTRODUCTION**

According to the 2018 World Health Organization Country Profiles, noncommunicable diseases are the leading cause of death globally, and one of the major health challenges of the 21st century. In 2016, they were responsible for 71% (41 million) of the deaths globally, with cardiovascular diseases, cancers, chronic respiratory diseases and diabetes being the major causes. Due to an increase in the prevalence of chronic illnesses, the number of prescriptions as well as their cost is rising rapidly. The latest OECD publication "Health at a Glance: Europe 2018" states that pharmaceuticals expenditure represents the third largest item of health care spending in the European Union (EU), with Croatia having one of the highest expenditures on medical goods (mainly pharmaceuticals) among the EU Member States.

Moreover, an ample evidence base suggests that patients are often inadequately treated or not offered therapies that are likely to bring benefit. Consequently, patients are at an increased risk of experiencing drug therapy problems (DTPs) which, if not resolved, have substantial unfavourable clinical repercussions and add substantial costs to the health care system.

One way to address these issues is by improving the health-care system delivery and medication management. This includes, but is not limited to, the use of multidisciplinary care teams to provide coordinated care and ensure safe and effective pharmacotherapy to patients. Comprehensive Medication Management (CMM) services offered by trained pharmacists can fill this gap by decreasing the unnecessary and often harmful use of medicines and consequent resulting complications.

Today there is a widely accepted notion that a patient care process must involve a professional who is capable of applying a logical, standardized and reproducible process to pharmacotherapy decisions. When medications were fewer in number, less complicated and more manageable, physicians were able to furnish this responsibility. However, this is no longer true. CMM services are supported by a vast evidence-based literature and grounded in the practice of pharmaceutical care, as proposed by Cipolle, Strand and Mozeley. It is also promoted by several organizations such as the American College of Clinical Pharmacy, Get the Medications Right Institute, and Patient-Centered Primary Care Collaborative, which includes more than 500 organisations, all active stakeholders in the health-care system. Thus, this service has a scientific and clinical base that attempts to systematize the work of the clinical pharmacist with the patient and in collaboration with other providers, in order to optimize the use of medications in individuals’ daily lives.

**THE NEED FOR MEDICATION MANAGEMENT SERVICES**

Over the past few decades, the use of medications has undergone significant changes ranging from increases in prescription numbers, increases in the number and type of practitioners with prescribing rights, rising costs of new medications, to the rise in the increasingly complex new and emerging therapies. Another important factor worth mentioning is the continued lack of a structured, systematic decision-making process for drug selection and dosing.

Existing evidence suggests that as much as one-fifth of all health spending is wasteful and could be reduced, or eliminated, without undermining health system performance. In fact, after inpatient and outpatient care, pharmaceuticals (excluding those used in hospitals) represented the third largest health care expense, accounting for one sixth of all health expenditure in the EU in 2016. The total retail pharmaceutical bill across the EU was more than EUR 210 billion in 2016, representing an increase of approximately 5% (in nominal terms) since 2010. In Croatia, prescription medications accounted for 87 - 90% of all medications financial costs from 2012 to 2016, growing about 3.5% annually, and reaching its peak of 10.2% in 2016. These trends indicate a need to manage the use of prescription medications more efficiently.

Inadequate medication management has other consequences, such as increased levels of drug-related morbidity and mortality, which are directly responsible for health care costs, and call for health-care system reform.

According to the latest data, more than 1.2 million people in EU countries died in 2015 from diseases and injuries that could have been avoided either through stronger public health policies or more effective and timely health care. Additionally, potentially avoidable hospital admissions for some chronic conditions, out of which diabetes, hypertension, heart failure, chronic obstructive pulmonary disease (COPD) and bronchiectasis and asthma stand out, consume over 37 million bed days each year. Over 4.6 million admissions were made for these five conditions in 2015, amounting to 5.6% of all admissions which might have been avoided. The estimated annual cost of drug-related morbidity and mortality resulting from nonoptimized medication therapy in the United States (US) was $528.4 billion, equivalent to 16% of total US health care expenditures in 2016.

Thus, governments and health plans pay for poor adherence to treatment, the lack of control of chronic diseases, and the development of complications in the long term. Additionally, in cases of multiple comorbidities, visits to different medical specialists concurrently, and without coordination or communication among them, often contribute to the worsening of medication related problems.

Hence, the expansion of CMM programs led by clinical pharmacists in collaboration with physicians and other licensed prescribers has been recommended in the United States as an effective and scalable approach to mitigate these avoidable costs and improve patient outcomes.

**MEDICATION MANAGEMENT SERVICES AS A SOLUTION TO THE PROBLEM**

A definition of medication management services

Comprehensive medication management services is defined as the standard of care that ensures each patient’s medications (whether they are prescription, nonprescription, alternative, traditional, vitamins, or nutritional supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given the comorbidities and other medications taken, and that the patient is able to take them as intended. The concept and definition of the service has evolved over the years. In 2003, the Center for Medicare and Medicaid Services recommended the provision of medication therapy management services as an additional new service required for patients receiving Medicare Part D benefits. There are a number of definitions for medication management services available, but today we rely on the definitions proposed by the Patient Centered Primary Care Collaborative, American Medical Association, and the Minnesota State Legislature.

CMM services is an evidence-based and patient-centered clinical practice, provided by pharmacist with an aim of preventing, identifying and resolving DTPs to optimize patients’ medication experience and...
clinical outcomes. Through this rational and standardized process, the pharmacist reviews the medications used by the patient and identifies possible problems associated with the indication, effectiveness, safety and compliance with the pharmacotherapy treatment. In addition to the comprehensive assessment of patient’s drug-related needs, CMM includes the development of an individualized care plan to determine desired goals of therapy with the patient, as well as appropriate follow-up to evaluate actual patient outcomes that result from the care plan. All of this occurs because the patient understands, agrees with, and actively participates in the treatment regimen, thus optimizing each patient’s medication experience and clinical outcomes.

The CMM services delivered in a health centre have the following five elements in common: a) the service needs to be delivered directly to a specific patient (as opposed to performing a prescription review without seeing the patient); b) it must include an assessment of the patient’s medication-related needs, followed by an individualized care plan and follow up; c) the care must be comprehensive, i.e. pharmaceutical care practitioner assesses all of the patient’s medications (prescribed, over-the-counter, supplements, herbal remedies etc.), since medications interact with other medications and impact all medical conditions; d) the work of pharmacists needs to be coordinated with physicians and other team members; and e) the service is expected to add unique value to the care of the patient.

The interventions proposed within the CMM services are grounded in the philosophy and ethics of the professional practice of pharmaceutical care and delivered according to the standards of practice for the patient care process described by the practice. The focus of CMM services is on improving patient's medication experience and clinical outcomes. Through this rational and standardized process, the pharmacist reviews the medications used by the patient and identifies DTPs. The value of Medication ManageMent Services (CMM) services has been observed in patients with medical conditions such as cardiovascular diseases (CVD) and diabetes, and improvement in patient care when pharmacists are located in primary care ambulatory clinics working side by side with the physicians and nurses. Particularly, the greatest improvement in patient’s clinical outcomes receiving CMM services has been observed in patients with medical conditions that are extremely costly and are associated with the use of multiple medications (hypertension, diabetes, CVD, COPD). Hence, patients with these comorbidities are considered great candidates to receive the service. According to the largest database published until now, the total number of 88,556 DTPs was identified and resolved in 22,694 patients receiving CMM services in a 4-year period. Out of 18,866 patients’ medical conditions that were not at goal at their first visit to pharmaceutical care practitioner, 74% of conditions improved or remained the same after receiving CMM services. A retrospective study from 2004, pharmaceutical care practitioners identified 3,407 DTPs in 2,985 patients during their patients’ first assessment, out of which 61% had one or more DTPs identified and resolved. As a result of pharmaceutical care provision, in one third of patients, medical conditions improved.
al showed that pharmacists identified and addressed 38,631 DTPs among 9,068 patients during a 10-year period, whereof 80% of DTPs were directly resolved with patients, without consulting physicians. More than a half of DTPs necessitated inclusion of a new medication or dosage increase, while only 16.5% were associated with non-adherence. Rao et al. showed that 81% of patients’ DTPs were resolved or well managed by pharmacists, while Borges et al. resolved 62.7% of DTPs in patients with type 2 diabetes. Moreover, CMM services have shown the positive impact on individual CV risk factors: blood pressure (12.28,31,40), glycated hemoglobin (HbA1c) (30.31,39) and LDL cholesterol12,30,40.

Furthermore, studies have demonstrated the economic and social welfare of CMM services17,32,34,41. Patients receiving face-to-face CMM services had lower total health expenditures, with the reduction in total annual health expenditures exceeding the cost of providing CMM services by as high as 12:1, and with the average ratio of 3:1 to 5:1 (return on investment, ROI)35. A report reviewing the team-based medication therapy management system in four clinics revealed that spending growth was 11% less in innovation clinics (team-based care that incorporates comprehensive medication therapy management) than that in 38 non-innovation clinics32. Furthermore, the median monthly health care costs per member, measured at five intervals over a 15-month period, were significantly lower in innovation than in non-innovation clinics36. The Ashville project, involving community pharmacy-based practitioners specially trained to address issues in patients with diabetes, asthma, CVD and depression, demonstrated a 4:1 ROI and a decrease in direct yearly average medical costs between $1200 and $1872 per patient32,43,44.

The value of this service has been recognized by patients who had the opportunity to use it as well as by physicians and other health care professionals, health plans, employers and payers. Firstly, it is worth mentioning that patients benefit not only from improved clinical outcomes, but also from having health care professionals who are willing and capable to understand their unique medication experience. Physicians profit by having pharmacotherapy experts managing complex therapies side by side, thus enabling them to have more time for diagnostics and quality medical care provision37,45. Finally, insurers pay only for medications that are appropriate, effective and safe for the patient, and are used as intended.

**Current Situation of CMM Services Across Europe**

Health systems across Europe have achieved remarkable progress in treating life-threatening diseases, yet more effective healthcare interventions are needed if we are to improve management of health problems in the community. While disparities in healthcare systems between the European countries persist, patient-centred practices, in which pharmacists are held accountable for patients’ clinical outcomes, are still underdeveloped and lack inclusion at the primary care level. In Europe, in spite of the widespread recognition of the need for medication management services, initiation and implementation of CMM services are lagging behind. Limited published data on CMM services implementation46 confirms that this service has not been developed or recognized in Europe, as it has been in the Anglo-Saxon countries especially USA and Australia12,47-49. Although supported by relevant laws, it seems that governments have not taken an active interest in promoting a movement toward pharmacists playing a major role in primary health care. The following text will not provide an in-depth description of the current situation regarding the status of medication management services in Europe, as this has been fully described elsewhere41, but rather shed a light on recent advancements that have occurred across European countries.

Integration of clinical pharmacist into general practitioner (GP) services in Great Britain began in 2015 when the National Health Service (NHS) England instigated the initiative and partly funded over 400 clinical pharmacists to provide support to almost 700 GP surgeries and more than seven million patients49. To date, over 1,000 full time equivalent clinical pharmacists provide the service across the country with a further 1,500 pharmacist roles planned by 202050,51. This far-sighted initiative came in response to considerations about general practice workforce capacity, where concerns about shortfalls in GP numbers have been raised52. However, it is unclear whether the patient care process proposed by Cipolle et al.53,54 is used as the theoretical framework to take care of the patients. Very recent publications from Iceland and Netherlands highlight the importance of developing pharmaceutical care practice separately from the dispensing process and in close cooperation with physicians, at the primary care level55,56. Netherlands is an interesting example of community pharmacy having a leading role in pharmaceutical care provision, with reimbursements for pharmaceutical care services being covered by the Dutch government and health insurance companies46.

Although it appears that the prerequisites for the implementation of medication management services are in place, at present the employment of CMM services in primary care is suboptimal, if any44. Namely, pharmacists lack access to patient information, they are short of clinical knowledge and skills, and the working processes of pharmacists and general practitioners match poorly. Nevertheless, attempts have been made to integrate a non-dispensing pharmacist in general practice and the results demonstrated favourable outcomes. Albeit, the process of care they employed did not follow the patient care process proposed by Cipolle et al.53,54. Although Iceland undoubtedly embraced the concept of pharmaceutical care, medication management services are still limited, and serious efforts will need to be invested before further development can occur48. General practitioners are not familiar with pharmaceutical care and additionally no such service is offered in pharmacies or primary care settings. Efforts have been made to introduce pharmacist-led pharmaceutical care into primary care clinics in Iceland in collaboration with GPs, and results showed that GPs would now like to have access to a pharmacist on a daily basis48. In Slovenia, consultations delivered by non-dispensing pharmacists as a part of medication review clinics started in 2012, and today they are running in over 30 health centres (altogether over 50 clinics available, however not running full time)35. However, lack of published data on clinical outcomes of this service limits us in making comparisons and conclusions on its effectiveness.

Spain has made progress towards the provision of clinical services mainly in community pharmacies. Considering the lack of published literature, pharmacists do not seem to be involved in direct patient care in ambulatory clinics or in the provision of CMM services. However, some very important initiatives have been made to prepare pharmacists to provide CMM services and to foster these services. The “Universidad de San Jorge” in Zaragoza offers a master program in which students are trained to care for real patients in collaboration with other members of the care team, which creatively includes...
**Table 1. Steps and activities that need to be accomplished to provide effective CMM services**

<table>
<thead>
<tr>
<th>STEPS AND ACTIVITIES</th>
<th>HEALTH PROFESSIONAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PATIENT REFERRAL AND RECRUITMENT</strong></td>
<td></td>
</tr>
<tr>
<td>Identify patients who benefit most from the service:</td>
<td></td>
</tr>
<tr>
<td>a) Patients who have not reached their therapeutic goal</td>
<td></td>
</tr>
<tr>
<td>b) Patients taking very complex dosage regimens</td>
<td></td>
</tr>
<tr>
<td>c) Patients who are frequently readmitted to the hospital</td>
<td></td>
</tr>
<tr>
<td>d) Patients experiencing adverse drug reactions</td>
<td></td>
</tr>
<tr>
<td>e) Patients needing prevention therapy</td>
<td></td>
</tr>
<tr>
<td>f) Patients who are having difficulty to understand and follow their medication regimen.</td>
<td></td>
</tr>
<tr>
<td><strong>THE PATIENT CARE PROCESS</strong></td>
<td></td>
</tr>
<tr>
<td>Assessment of the patient’s drug related needs</td>
<td></td>
</tr>
<tr>
<td>Meet the patient and uncover patient’s medication experience (preferences, expectations and beliefs).</td>
<td></td>
</tr>
<tr>
<td>Collect patient specific information: demographic information, social history (alcohol, tobacco, caffeine) and clinical information (relevant medical history, medication history, current medication list including prescription and over-the-counter medications, herbal remedies, supplements and medications used for a limited period of time, and relevant laboratory values) including allergies, side-effects and immunizations.</td>
<td></td>
</tr>
<tr>
<td>Prioritize patients’ active medical conditions and medication-related needs.</td>
<td></td>
</tr>
<tr>
<td>Identification of drug-related problems</td>
<td></td>
</tr>
<tr>
<td>Determine that all the patient’s medications are properly indicated, the most effective available, the safest possible, and that the patient is able and willing to take the medication as intended.</td>
<td></td>
</tr>
<tr>
<td>Analyse the assessment data to determine if any drug therapy problems are present.</td>
<td></td>
</tr>
<tr>
<td>Care plan development</td>
<td></td>
</tr>
<tr>
<td>Identify goals of therapy for each indication managed with drug therapy.</td>
<td></td>
</tr>
<tr>
<td>Develop a care plan that includes interventions to resolve current drug therapy problems, prevent potential drug therapy problems and achieve goals of therapy.</td>
<td></td>
</tr>
<tr>
<td>Discuss and negotiate the care plan with the patient and his prescriber, ensure patient’s and prescriber’s understanding and agreement with the plan, and schedule follow-up evaluation.</td>
<td></td>
</tr>
<tr>
<td>Document the care plan which includes all the steps and clinical status determined for every patient’s medical condition.</td>
<td></td>
</tr>
<tr>
<td>Follow-up evaluation</td>
<td></td>
</tr>
<tr>
<td>Make follow-up evaluation for each patient to reassess whether any new drug therapy problems have developed, monitor patient’s progress toward the achievement of the goals of therapy, and refine the care plan to ensure therapy goals are achieved and medication therapy is optimized.</td>
<td></td>
</tr>
<tr>
<td><strong>CARE COORDINATION BY ALL TEAM MEMBERS – REPEATING PROCESS-CARE</strong></td>
<td></td>
</tr>
</tbody>
</table>
a psychologist, a philosopher and an anthropologist. Moreover, in 2012 the “Sociedad Española de Optimización de la Farmacoterapia (SEDOF)” was founded in Andalucía with the goal to congregate pharmacists interested in developing CMM services\(^2\). SEDOF promotes the “Escuela de optimización de la farmacoterapia”, which is in its 14th version. These courses include discussions on patient cases and reflect on specific aspects of patient care within the framework of CMM services. Croatia is one of the countries where the implementation of comprehensive medication management services started only recently. Although Croatia embraces the concept of pharmaceutical care practice, policies and legal regulations supporting the provision of CMM services on a much larger scale, still need to be developed. According to the Law on Pharmacy\(^3\), Croatian pharmacists are obligated to provide pharmaceutical care in cooperation with other health care workers. However, the same Law ties pharmaceutical activities exclusively to community and hospital pharmacies, and precludes pharmacists from providing care at locations where their expertise is indispensable, such as nursery homes, health care centres and hospital wards. The abovementioned is only one of the existing legal obstacles that needs to be addressed prior to CMM services implementation. Nevertheless, pharmacy graduates in Croatia are competent in providing clinical services more than ever before, mainly due to the curriculums reform that has commenced in the academic year 2005/2006 due to which the focus has shifted from more chemically oriented pharmaceutical sciences toward clinically based and patient-focused courses. In order to harmonize our programme with the EU Directive 2005/36/EC, Faculty of Pharmacy and Biochemistry University of Zagreb (UoZ) introduced an obligatory six-month traineeship and new modules (e.g. Pharmacotherapy and Clinical Pharmacy, Pharmaceutical Care, Consultation Skills, Health legislation, Sociology in Pharmacy etc.) in the academic year 2011/2012 (58). Furthermore, since the academic year 2010/2011, the postgraduate specialist study program “Clinical pharmacy”\(^4\) has been offered at the Faculty of Pharmacy and Biochemistry UoZ, and it precedes the 3-year Specialization in Clinical Pharmacy assigned from the Ministry of Health. All of these changes equipped Croatian pharmacists with clinical knowledge and skills needed for engaging in clinical activities. Nevertheless, up until now the government did not provide any standardized and legal framework allowing for the development of strategies to broaden pharmacists’ responsibilities and expand those into the integrated health care system. Hence, pharmacists’ educational requirements for CMM services provision in Croatia still need to be defined within the profession itself and subsequently legalized. On the bright side, a small group of younger pharmacists in Croatia is currently taking the lead and creating new services. The CMM services are piloted by two pharmacists from the UoZ Faculty of Pharmacy and Biochemistry at the primary care clinic, Health Centre Zagreb Centre, since January 2018\(^5\). Until now, this is the only county health centre providing CMM services at the primary care level in Croatia. This positive development, even if it is small, holds promise for the further progression of medication management services in Croatia. The examples of the abovementioned countries showcase that a process of comprehensively and rationally managing patients’ medications is not systematically implemented across European countries and that the countries are struggling to find the best solution in that endeavour. Due to disparate standing points, resulting from different cultural, sociolegal and ethical backgrounds, one cannot foresee a direction countries will take and the rate at which the change will be occurring. In conclusion, for CMM services to become a reality in Europe and elsewhere, it is of paramount importance that pharmacists who will provide these services have one professional practice as their theoretical and ethical foundation. Thus, we will be able to teach to this practice and pharmacists will be able to communicate between themselves and to others what they do for patients. In addition, only then we will be able to evaluate the results of what we do, compare between ourselves and improve upon that. That is how all other members of the healthcare team work, which reflects the rules of patient care worldwide. Moreover, we will need policy to support the development and implementation of these services in a manner that can be reimbursed, reproducible and sustainable over time. What we really need are governments and health plans willing to support clinical pharmacists, namely professionals willing and capable to provide this service, as it will only live its full potential when we have well trained and experienced practitioners. To achieve this, clinical pharmacists need not only to expand their clinical knowledge by having experience with lots of patients, but also to reflect upon and assess these experiences. We will not have clinical experts until we have pharmacists that can provide direct patient care as a full-time job, caring for as many patients as possible. Only then will they gain expertise and exert their full potential. Consequently, we will know what this service is able to produce in terms of clinical outcomes and healthcare cost reduction. We cannot emphasize enough that the policy piece is key here. We need innovators, forward thinkers to support clinical pharmacists as they work on building their clinical practices and expertise. In the end, that is what patients deserve from us.

**Author contributions:** All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
38. Rao D, Gilbert A, Strand LM, Cipolle RJ. Drug therapy problems found in ambulatory patient populations in Minnesota and South


48. Torkjensen I. More than 400 pharmacists will be recruited to GP surgeries by next year. BMJ. 2015;351:h6167. doi: 10.1136/bmj.h6167.


52. Centre for Workforce Intelligence. In-depth review of the general practitioner workforce. London: Centre for Workforce Intelligence. 2014.


